Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties
10x Genomics(US:TXG) Benzinga·2025-02-13 20:10On Wednesday, 10x Genomics Inc TXG reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of $(0.30).The single-cell and spatial biology company reported quarterly sales of $165.02 million, down 10% year over year, beating the consensus of $159.39 million.Gross margin was 67% for the fourth quarter of 2024 compared to 63% a year ago, primarily due to product mix changes.10x Genomics' instruments sales fell to $24.35 million from $38.4 million a year ago. This included $10.93 million f ...